Ge Healthcare Technologies Inc. (GEHC)
NASDAQ:GEHC
Want to see GEHC full AI Analyst Report?
GEHC Stock Chart & Stats
$74.66
$3.08(3.69%)
At close: 4:00 PM EST
$74.66
$3.08(3.69%)
Day’s Range― - ―
52-Week Range$58.75 - $89.77
Previous CloseN/A
Volume1.76M
Average Volume (3M)4.93M
Market Cap
$28.02B
Enterprise Value$36.11B
Total Cash (Recent Filing)$2.29B
Total Debt (Recent Filing)$10.58B
Price to Earnings (P/E)18.7
Beta1.22
Next Earnings
Aug 05, 2026EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend Yield0.17%
Share Statistics
EPS (TTM)3.30
Shares Outstanding454,891,780
10 Day Avg. Volume4,589,507
30 Day Avg. Volume4,932,619
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit4.25
Enterprise Value/Ebitda10.63
Forecast
1Y Price Target
$77.18Price Target Upside3.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.88
Revenue Forecast (FY)$21.80B
Bulls Say, Bears Say
Bulls Say
Strong Backlog & Order CoverA $21.8B record backlog and 1.07x book-to-bill provide durable revenue visibility across quarters, smoothing capital-equipment cyclicality. This backlog supports predictable service, upgrades and consumable demand, underpinning medium-term revenue and cash flow conversion.
Recurring Services RevenueHigh-margin services growth strengthens recurring revenue mix and margin stability. A larger installed base drives spare parts, maintenance and upgrades, improving cash visibility and defensive resilience through capital spending cycles over the next several years.
Regulatory Wins & Product InnovationRecent product and regulatory milestones (photon-counting CT approvals, MR clearances) accelerate commercialization of differentiated systems. Sustained innovation and clearances expand addressable markets, support premium positioning and foster durable adoption by hospitals and research centers.
Bears Say
Moderate LeverageDebt near parity with equity limits financial flexibility for M&A, R&D spend or cyclical shocks. For a healthcare tech company, elevated leverage raises refinancing and covenant risk and reduces room to opportunistically invest if operating margins soften.
Weaker Recent Cash ConversionA meaningful TTM decline in free cash flow and weaker cash conversion constrains capital allocation choices. Lower FCF reduces capacity for debt paydown, R&D and buybacks, making the company more sensitive to operational headwinds over the medium term.
Margin Pressure From Inflation & Supply IssuesMaterial inflation (~$250M), tariffs and supplier-related quality/recall impacts compress margins and force price/cost actions. Persistent input-cost and tariff uncertainty can depress profitability and delay margin recovery, pressuring free cash flow and returns over multiple quarters.
GE Healthcare Technologies Inc News
GEHC FAQ
What was Ge Healthcare Technologies Inc.’s price range in the past 12 months?
Ge Healthcare Technologies Inc. lowest stock price was $58.75 and its highest was $89.77 in the past 12 months.
What is Ge Healthcare Technologies Inc.’s market cap?
Ge Healthcare Technologies Inc.’s market cap is $28.02B.
When is Ge Healthcare Technologies Inc.’s upcoming earnings report date?
Ge Healthcare Technologies Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 44 days.
How were Ge Healthcare Technologies Inc.’s earnings last quarter?
Ge Healthcare Technologies Inc. released its earnings results on Apr 29, 2026. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.045 by -$0.055.
Is Ge Healthcare Technologies Inc. overvalued?
According to Wall Street analysts Ge Healthcare Technologies Inc.’s price is currently Undervalued.
Does Ge Healthcare Technologies Inc. pay dividends?
Ge Healthcare Technologies Inc. pays a Quarterly dividend of $0.035 which represents an annual dividend yield of 0.17%. See more information on Ge Healthcare Technologies Inc. dividends here
What is Ge Healthcare Technologies Inc.’s EPS estimate?
Ge Healthcare Technologies Inc.’s EPS estimate is 1.03.
How many shares outstanding does Ge Healthcare Technologies Inc. have?
Ge Healthcare Technologies Inc. has 454,891,780 shares outstanding.
What happened to Ge Healthcare Technologies Inc.’s price movement after its last earnings report?
Ge Healthcare Technologies Inc. reported an EPS of $0.99 in its last earnings report, missing expectations of $1.045. Following the earnings report the stock price went down -13.161%.
Which hedge fund is a major shareholder of Ge Healthcare Technologies Inc.?
Currently, no hedge funds are holding shares in GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.18 (3.38% Upside)
$77.18 (3.38% Upside)
Blogger Sentiment
Bullish
GEHC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 723.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.17%
12-Months-Change
Fundamentals
Return on Equity
14.77%
Trailing 12-Months
Asset Growth
10.54%
Trailing 12-Months
Company Description
Ge Healthcare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
GEHC Company Deck
GEHC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging top-line execution, product/regulatory milestones, a record backlog and strategic progress (Flyrcado ramp, Photonova approvals, Intelerad acquisition, organizational realignment) against meaningful near-term profitability headwinds from supplier issues, tariffs and material inflation (~$250M gross impact). Management maintained revenue guidance but prudently reduced earnings guidance and emphasized mitigation actions whose benefits are weighted to the back half of 2026. The tone was confident on medium-term growth while realistic on near-term margin pressure.View all GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
GEHC Stock 12 Month Forecast
Average Price Target
$77.18
▲(3.38% Upside)
Technical Analysis
Veeva Systems
―
Healthequity
―
Doximity
―
Tempus AI, Inc. Class A
―
Hinge Health, Inc. Class A
―
Ownership Overview
0.30% Insiders
32.73% Mutual Funds
30.95% Other Institutional Investors
5.52% Public Companies and Individual Investors